Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Cash (2020 - 2025)

Historic Change in Cash for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $53.9 million.

  • Mirum Pharmaceuticals' Change in Cash rose 63360.06% to $53.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 17419.44%. This contributed to the annual value of -$63.4 million for FY2024, which is 14004.35% down from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Change in Cash of $53.9 million as of Q3 2025, which was up 63360.06% from $16.4 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Change in Cash registered a high of $147.8 million during Q2 2023, and its lowest value of -$69.3 million during Q2 2024.
  • For the 5-year period, Mirum Pharmaceuticals' Change in Cash averaged around $7.4 million, with its median value being $1.3 million (2021).
  • In the last 5 years, Mirum Pharmaceuticals' Change in Cash surged by 154305.25% in 2023 and then tumbled by 27322.93% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Change in Cash (Quarter) stood at $75.5 million in 2021, then tumbled by 110.27% to -$7.8 million in 2022, then tumbled by 115.74% to -$16.7 million in 2023, then soared by 97.22% to -$466000.0 in 2024, then soared by 11666.31% to $53.9 million in 2025.
  • Its last three reported values are $53.9 million in Q3 2025, $16.4 million for Q2 2025, and -$10.7 million during Q1 2025.